Home Ubiquitin DUB

DUB Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S7130 PR-619 PR-619 is a non-selective, reversible inhibitor of the deubiquitinylating enzymes (DUBs) with EC50 of 1-20 μM in a cell-free assay. This compound activates autophagy.
Transl Androl Urol, 2026, 15(2):55
Cell Insight, 2026, 5(3):100322
Cancer Immunol Res, 2025, 10.1158/2326-6066.CIR-24-1194
Verified customer review of PR-619
S7132 P5091 (P005091) P5091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM and the closely related USP47.
Mol Metab, 2025, 94:102111
J Cell Mol Med, 2025, 29(19):e70855
Neoplasia, 2025, 66:101192
Verified customer review of P5091 (P005091)
S7134 IU1 IU1 is a cell-permeable, reversible and selective proteasome inhibitor of human USP14 with IC50 of 4.7 μ M, 25-fold selective to IsoT. This compound induces autophagy.
Molecular Medicine, May 2, 2025, 163
Translational Andrology and Urology, February 11, 2026, 55
Cell Death & Disease, August 21, 2021, 803
Verified customer review of IU1
S7133 P22077 P22077 is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM, also inhibits the closely related USP47.
J Mol Cell Cardiol, 2026, 210:109-126
Int J Mol Sci, 2024, 25(5)2768
Hepatol Commun, 2024, 8(4)e0405
S4920 b-AP15 b-AP15 (NSC687852) is a deubiquitinases inhibitor for 19S proteasomes activity of Ub-AMC cleavage with IC50 of 2.1 μM.
Transl Androl Urol, 2026, 15(2):55
Nat Cell Biol, 2025, 27(9):1448-1464
J Control Release, 2025, 380:417-432
Verified customer review of b-AP15
S7529 ML323 ML323 displays reversible, nanomolar inhibitory activity and excellent selectivity toward USP1/UAF1 with IC50 of 76 nM.
Transl Androl Urol, 2026, 15(2):55
Cancers (Basel), 2025, 17(17)2864
Oncol Res, 2025, 33(1):213-224
S7135 LDN-57444 LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3.
Transl Androl Urol, 2026, 15(2):55
Stem Cell Res Ther, 2025, 16(1):271
J Transl Med, 2024, 22(1):478
Verified customer review of LDN-57444
S7140 TCID TCID is a DUB inhibitor for ubiquitin C-terminal hydrolase L3 with IC50 of 0.6 μM, 125-fold selective to L1.
Journal of Medicinal Chemistry, October 27, 2022, 13645-13659
Cellular Signalling, May 17, 2025, 111875
Nature Communications, May 16, 2025, 4564
S8288 VLX1570 VLX1570 is a competitive inhibitor of proteasome DUB activity, with an IC50 of ~10 μM in vitro.
Commun Biol, 2024, 7(1):25
Frontiers in Pharmacology, 2022, 778216
PLoS One, 2022, 17(7):e0271245
S6877 EOAI3402143 EOAI3402143 is a dose-dependent inhibitor of Usp9x, Usp24 and Usp5 that increases tumor cell apoptosis, and fully blocks or regresses myeloma tumors in mice.
Translational Lung Cancer Research, October 2021, 3995-4011
Cancer Cell, January 2026, S1535-6108(25)00547-1
Cell Reports Medicine, April 2023, 101007
S6748 ML364 ML364 is a small molecule inhibitor of the deubiquitinase USP2 with an IC50 of 1.1 μM in a biochemical assay using an internally quenched fluorescent di-ubiquitin substrate.
Journal for ImmunoTherapy of Cancer, 2026, e013498
Transl Androl Urol, 2026, 15(2):55
Nat Commun, 2025, 16(1):4564
S8904 USP25/28 inhibitor AZ1 AZ1 is a potent and noncompetitive dual Inhibitors of the ubiquitin-specific protease (USP) 25/28 with IC50s of 0.62 μM and 0.7 μM in Ub-RH110 assay,respectively.
Transl Androl Urol, 2026, 15(2):55
Cell Death Dis, 2025, 16(1):305
Mol Oncol, 2022, 10.1002/1878-0261.13217
S8967 XL177A XL177A is a potent, selective and irreversible inhibitor of Ubiquitin specific peptidase 7 (USP7) with IC50 of 0.34 nM.
Cancer Cell, 2026, S1535-6108(25)00547-1
Transl Androl Urol, 2026, 15(2):55
Queen's University Belfast, 2023,
S0515 PLpro inhibitor  PLpro inhibitor (compound 6) is a potent papain-like protease (PLpro)/deubiquitinase (DUBs) inhibitor with IC50 of 2.6 μM and EC50 of 13.1 μM that blocks SARS virus replication.
PLoS Pathog, 2023, 19(8):e1011592
bioRxiv, 2022, 2022.08.06.503039
S6883 HBX 19818 HBX19818 is a specific inhibitor of USP7 with an IC 50 of 28.1 μM.
Queens University Belfast (Doctoral Thesis), 2023, nan
Queen's University Belfast, 2023,
S0399 SJB2-043 SJB2-043 is a potent USP1 inhibitor that inhibits the activity of native USP1/UAF1 with IC50 of 544 nM.
Frontiers in Pharmacology, June 04 2021, 695009
Autophagy, 2022, 1801-1821
Frontiers in Pharmacology, 2021, 695009
E1479 I-138 I-138 is an orally active, potent reversible inhibitor of USP1-UAF1 with IC50 0f 4.1 nM. This compound is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells.
J Biol Chem, 2025, 301(3):108190
E0392 Dubs-IN-1 Dubs-IN-1 is an active inhibitor of ubiquitin-specific proteases (USPs), with an IC50 of 0.85 μM for USP8.
Autophagy, 2022, 1801-1821
E1330 Usp22i-S02 Usp22i-S02(USP22-IN-1, compound S02) is a potent inhibitor of ubiquitin specific peptidase 22 (USP22). It showed anticancer activity by suppressing Foxp3 expression in T-regulatory cells.
Int Immunopharmacol, 2025, 153:114538
S6845 GRL0617 GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLPro)/deubiquitinase with IC50 of 0.6 μM and Ki of 0.49 μM. This compound inhibits SARS-CoV viral replication in Vero E6 cells with EC50 of 15 microM and has no associated cytotoxicity.
Journal of Virology, 2024, e00855-24
J Virol, 2024, e0085524.
S6933 GEN-6776 GNE-6776 is a potent, non-covalent, selective and orally bioavailable inhibitor of USP7 with IC50 of 1.34 μM and 0.61 μM for full length USP7 and USP7 catalytic domain, respectively.
Queen's University Belfast, 2023,
S6878 GSK2643943A GSK2643943A is an inhibitor of deubiquitylating enzyme (DUB) with IC50 of 160 nM for USP20/Ub-Rho.
Transl Androl Urol, 2026, 15(2):55
Nature, 2020, 10.1038/s41586-020-2928-y
S4922 NSC 632839 NSC 632839 is not only a DUB inhibitor, but also a deSUMOylase inhibitor, it inhibits USP2, USP7, and SENP2 with EC50 of 45 μM, 37 μM, and 9.8 μM, respectively.
E5945 Wu-5 Wu-5 is an inhibitor of USP10 that blocks its activity in vitro with an IC50 of 8.3 µM. It also promotes FLT3-ITD degradation and synergistically enhances crenolanib-induced apoptosis.
E1633 BAY-805 BAY-805 is a potent, selective, and cell-active inhibitor that non-covalently targets the catalytic activity of USP21, a member of the ubiquitin-specific protease (USP) subfamily of deubiquitinating enzymes (DUBs).
E6502New USP7-IN-1 USP7-IN-1 (Example 2) is a selective and reversible inhibitor of USP7 with an IC50 of 77 Μm and exhibits antiproliferative activity, inhibiting the growth of HCT116 colorectal cancer cells with a GI50 of 67 μM.
E5999 CT1113 CT1113 is a potent dual inhibitor of USP25 and USP28 that effectively reduces c-MYC levels and exhibits strong anti-tumor activity. It can be used in research on colon and pancreatic cancers.
E1098 MF-094 MF-094, a potent and selective USP30 inhibitor (IC50=0.12 μM), accelerates diabetic wound healing by inhibiting the NLRP3 inflammasome.
Transl Androl Urol, 2026, 15(2):55
E0389 DUBs-IN-2 DUBs-IN-2 is a potent inhibitor of USP8 deubiquitinating enzymes. 
Transl Androl Urol, 2026, 15(2):55
E0947 Iu1-248 Iu1-248, a derivative of IU1, is a potent and selective ubiquitin specific peptidase 14 (USP14) inhibitor with an IC50 of 0.83 μM.
E1118 SJB3-019A SJB3-019A is a potent inhibitor of USP1 that significantly suppresses cell proliferation and induces apoptosis in B-cell acute lymphoblastic leukemia (B-ALL) cells. It also promotes DNA-binding-1 (ID1) degradation in K562 cells.
E6603New USP5-IN-1 USP5‑IN‑1 (compound 64) is a selective, competitive inhibitor of the USP5 zinc finger ubiquitin‑binding domain (ZnF‑UBD) with a KD of 2.8 μM. It also suppresses USP5 catalytic activity and inhibits the hydrolysis of unanchored ubiquitin chains.
S6943 IU1-47 IU1-47 is a potent and specific inhibitor of USP14 with an IC50 of 0.6 μM. This compound shows ∼33-fold selectivity for USP14 over USP5 (IsoT).
E6671New CMPD-39 CMPD-39 (Compound 39) is a selective non-covalent inhibitor of USP30 with an IC50 of ~20 nM in in vitro enzyme assays.
S0884 RA-9 RA-9 is a cell-permeable, potent and selective inhibitor of proteasome-associated deubiquitinating enzymes (DUBs) with favorable toxicity profile and anticancer activity. This compound selectively induces apoptosis in ovarian cancer cell lines.
S2913 BAY 11-7082 (BAY 11-7821) BAY 11-7082 (BAY 11-7821) is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 with IC50 of 0.19 μM and 0.96 μM, respectively. BAY 11-7082 induces apoptosis and S phase arrest in gastric cancer cells.
Research (Wash D C), 2026, 9:1190
J Dairy Sci, 2026, 109(3):2890-2903
Transl Androl Urol, 2026, 15(2):55
Verified customer review of BAY 11-7082 (BAY 11-7821)
S2243 Degrasyn (WP1130) Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). This compound induces apoptosis and blocks autophagy.
Nat Commun, 2025, 16(1):628
Nat Commun, 2025, 16(1):1313
Cell Death Dis, 2025, 16(1):564
Verified customer review of Degrasyn (WP1130)
S7888 Spautin-1 Spautin-1 is a potent and specific autophagy inhibitor, and inhibits the deubiquitinating activity of USP10 and USP13 with IC50 of ∼0.6-0.7 μM. This compound enhances apoptosis.
Life Science Alliance, September 27, 2021, e202101137
Scientific Reports, July 07, 2022, 11533
OncoImmunology, February 15, 2018, e1431086
Verified customer review of Spautin-1
S3692 N-Ethylmaleimide (NEM) NEM (N-Ethylmaleimide) is an organic compound that is derived from maleic acid. It is an irreversible inhibitor of all cysteine peptidases, with alkylation occurring at the active site thiol group. N-Ethylmaleimide (NEM) inactivates endogenous deubiquitinating enzymes (DUBs). N-Ethylmaleimide (NEM) specifically inhibits phosphate transport in mitochondria.
Autophagy, 2026, 22(3):526-544
Nat Commun, 2025, 16(1):7812
Inflammation, 2025, 10.1007/s10753-025-02273-w
E1214 KSQ-4279 (USP1-IN-1) KSQ-4279 (USP1-IN-1) is an orally bioavailable selective inhibitor of the ubiquitin specific protease 1 (USP1) with anti-proliferative activity. KSQ-4279 also exhibits synergistic activity in combination with PARP inhibitors.
Cancer Res, 2024, 84(20):3419-3434
Sci Adv, 2024, 10(46):eadp6567